Analyst Profile

Followed by 4,631 followers
.
Kevin DeGeeter

Kevin DeGeeter

Oppenheimer
Wall Street Analyst
#296 out of 8,141 Wall Street Analysts
#569 out of 24,284 experts

Success Rate

38%
138 out of 365 transactions made a profit

Average Return

+20.80%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Kevin DeGeeter's trades since 2013 and holding each position for 1 Year would result in 37.81% of your transactions generating a profit, with an average return of 20.8% per rating.

Stock Rating Distribution

625Ratings
87.20% Buy
12.16% Hold
0.64% Sell
Distribution of Kevin DeGeeter's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Bionano Genomics
(BNGO)
Rating:Buy
Date:Nov 13, 2020 - Nov 13, 2021
Return:+800.00%
The most profitable rating made by Kevin DeGeeter

Kevin DeGeeter's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
Response Genetics
Aug 08, 2013
Buy
Reiterated
$2.75
(274999900.00% Upside)
2Ratings
0.00%
Myrexis
Oct 01, 2013
Buy
Upgraded
1Ratings
0.00%
Navidea
Nov 07, 2013
Buy
Reiterated
$3.00
(1113.10% Upside)
2Ratings
0.00%
Gilead Sciences
Jan 26, 2014
Buy
Assigned
$86.00
(-2.08% Downside)
2Ratings
0.00%
BioCryst
Feb 28, 2014
Hold
Initiated
1Ratings
0.00%
Amgen
Apr 04, 2014
Hold
Assigned
$121.00
(-57.75% Downside)
2Ratings
0.00%
ATRS
Antares Pharma
May 09, 2014
Buy
Assigned
5Ratings
0.00%
Curis
Aug 07, 2014
Buy
Assigned
$3.00
(271.79% Upside)
4Ratings
0.00%
Genetic Technologies
Aug 15, 2014
Hold
Downgraded
5Ratings
0.00%
Incyte
Oct 30, 2014
Buy
Assigned
$75.00
(-5.86% Downside)
9Ratings
0.00%
List of latest recommendations made by Kevin DeGeeter. Click to expand and see Kevin DeGeeter's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >